Increased calls for publishing negative clinical trial data
By Mary Gabb ( mary.gabb@rxcomms.com ) A negative result is defined as one that shows evidence of absent (or no) effect of an intervention; it is not due to absence…
DetailsIs the NHS on its last legs?
By Ruth Whittington (ruth.whittington@rxcomms.com) With the NHS in the UK nearing its 60th birthday, there’s been considerable talk about whether the system should be put into retirement. At the recent…
Details‘Big box’ companies and public health
By David Woods (david.woods@rxcomms.com) Whether it’s because of a shortage of primary care physicians, impatience at the length of time it takes to see one, or simply increasing costs, the…
DetailsThe mean versus the gene: will national healthcare systems ever adopt personalised medicine?
By John F P Bridges While outcomes for any given treatment differ significantly among patients, national healthcare systems continue to take a top down population perspective in reviewing not only…
DetailsRegulating DTC ads – Are we attempting to herd cats?
By Mary Gabb (mary.gabb@rxcomms.com) In a previous issue of HOC , we outlined some of the commonly expressed pros and cons of direct-to-consumer advertising (DTCA), which is currently allowed only…
Detailswww.PatientsLikeMe.com – The power of patient-provided information
By Julie Stauffer (julie.stauffer@rxcomms.com) Pharmaceutical companies depend on data – and lots of it – to develop drugs and measure their effectiveness. And many patients are eager to supply that…
DetailsCanada healthcare – from paper to pixels
By Ruth Whittington (ruth.whittington@rxcomms.com) Many of us in health economics and outcomes research look at Canada as one of the leaders in the field; along with Australia , Canada was…
DetailsTop Ten Health Economics Journals
By Julie Stauffer (julie.stauffer@rxcomms.com) Staying on top of new developments can be a daunting task in today’s hyper-connected world. If you’re feeling swamped in a sea of information, make the…
DetailsISMPP: Former Merck CEO outlines three ways pharma companies can regain lost prestige
By David Woods (david.woods@rxcomms.com) While the Golden Age of the pharmaceutical industry is over, and its reputation similar to that of the tobacco and oil industries, there is hope at…
DetailsIs the value of drug innovation poorly understood?
By David Woods (david.woods@rxcomms.com) Speaking at the March World Health Care Conference in Washington , DC , Joshua J Ofman, MD, vice president, global coverage and reimbursement for Amgen, said…
Details